Idorsia Ltd (OTCMKTS:IDRSF – Get Free Report)’s share price was down 1.9% on Thursday . The company traded as low as $7.75 and last traded at $7.75. 2,850 shares were traded during mid-day trading, a decline of 74% from the average session volume of 11,030 shares. The stock had previously closed at $7.90.
Wall Street Analysts Forecast Growth
Separately, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Idorsia in a report on Monday, August 3rd. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Idorsia has an average rating of “Moderate Buy”.
Get Our Latest Stock Analysis on Idorsia
Idorsia Stock Down 1.9%
About Idorsia
Idorsia Ltd is a Swiss biopharmaceutical company founded in 2017 as a spin-off from Actelion following its acquisition by Johnson & Johnson. Headquartered in Allschwil, Switzerland, Idorsia focuses on the discovery, development and commercialization of innovative small-molecule therapeutics. The company’s R&D efforts span multiple therapeutic areas, including neuroscience, cardiovascular and immunology, with the goal of addressing unmet medical needs through novel mechanisms of action.
Among Idorsia’s lead products is daridorexant, a dual orexin receptor antagonist developed for the treatment of insomnia.
Further Reading
- Five stocks we like better than Idorsia
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.
